Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
SWOG Cancer Research Network
Hoosier Cancer Research Network
Eastern Cooperative Oncology Group
University of Minnesota
Association Européenne de Recherche en Oncologie